Symbols

ABEO

Abeona Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 0

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

MACD Golden Cross

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ABEO

Abeona Therapeutics, Inc.

A clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases

Industry

Biological Technology

Established Date

Listing Date

12/19/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

226

Fiscal Year Ends

12-31

Website

www.abeonatherapeutics.com

Security Type

Common stock

Office address

6555 Carnegie Avenue, 4th Floor, Cleveland, OH 44103

Business

Introduction

Abeona Therapeutics, Inc., was incorporated in Wyoming in 1974. The company is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. On April 28, 2025, the U.S. Food and Drug Administration approved ZEVASKYN (prademagene zamikeracel) genetically modified cell sheet as the first and only autologous cell-based gene therapy for the treatment of wounds in adults and children with RDEB, a severe and debilitating hereditary skin disease. RDEB cannot be cured, and ZEVASKYN is the only U.S. Food and Drug Administration-approved product that can treat RDEB wounds in one go. ZEVASKYN has been awarded the orphan drug and rare pediatric disease designation by the U.S. Food and Drug Administration.

Company Financials

EPS

ABEO has released its 2025 Q4 earnings. EPS was reported at -0.36, versus the expected -0.33, missing expectations. The chart below visualizes how ABEO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ABEO has released its 2025 Q4 earnings report, with revenue of 5.42M, reflecting a YoY change of NaN%, and net profit of -20.46M, showing a YoY change of -120.17%. The Sankey diagram below clearly presents ABEO's revenue sources and cost distribution.